Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262)

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 5, 1998, Pages 435-443

  McCance Katz, Elinore F ^a,b   Rainey, Petrie M ^a   Jatlow, Peter ^a   Friedland, Gerald ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Drug interaction; Methadone; Pharmacokinetics; ZDV; Zidovudine

Indexed keywords

METHADONE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG GLUCURONIDATION; FEMALE; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHADONE TREATMENT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032529385     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199808150-00004     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 1996;8:4-33.
2. Haverkos HW. Infectious diseases and drug abuse: prevention and treatment in the drug abuse treatment system. J Subst Abuse 1991; 8:269-75.
3. Brown B. AIDS and the provision of drug user treatment. Int J Addict 1991;25:1503-14.
4. Alcabes P, Friedland G. Injection drug use and human immunodeficiency virus infection. Clin Infect Dis 1995;20:1467-79.
5. O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection drug users with human immunodeficiency virus infection. N Engl J Med 1994;331:450-9.
6. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992;327:1697-703.
7. El Sadr W, Capp S. The challenge of minority recruitment in clinical trials. JAMA 1992;267:954-7.
8. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997;277:1962-9.
9. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azido-thymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192-7.
10. Kreek MJ, Garfield JW, Gutjahr CL, Guisti LM. Rifampin induced methadone withdrawal. N Engl J Med 1976;294:1104-6.
11. Schwartz EL, Brechbuhl AB, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J Acquir Immune Defic Syndr 1992;5:619-26.
12. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. Am J Psychiatry 1995;152(Suppl):5-59.
13. Wall TL, Sorensen JL, Batki SL, Delucchi KL, London JA, Chesney MA. Adherence to zidovudine (ZDV) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend 1995;37: 261-9.
14. Jaffe JH, Epstein S, Ciraulo DA. Opioids. In Ciraulo D, Shader R, eds. Clinical manual of chemical dependence. Washington, DC: American Psychiatric Association Press, 1991:108-11.
15. Dole VP, Kreek MJ. Methadone plasma levels: sustained by a reservoir of drug in tissues. Proc Natl Acad Sci USA 1973;70:10.
16. Wilde MI, Langtry DI. Zidovudine. Drugs 1993;46:515-78.
17. Morse GD, Shelton MJ, O'Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogs. Clin Pharmacokinet 1993; 24:101-23.
18. Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3′-azido-2′3′-dideoxythymidine (zidovudine) and related dideoxynucleotides. N Engl J Med 1989;321:726-38.
19. Langtry HD, Campoli-Richards DM. Zidovudine: a review of its pharmacodyamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1989;37:408-50.
20. Good SS, Koble CS, Crouch R, Johnson RL, Rideout JL, de Miranda P. Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans. Drug Metab Dispos Biol Fate Chem 1990;18:321-6.
21. Taburet AM, Singlas E. Drug interactions with antiviral drugs. Clin Pharmacokinet 1996;30:385-401.
22. Stagg MP, Cretton EM, Kidd L, Diasio RB, Sommadossi JP. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin Pharmacol Ther 1992;51:668-76.
23. Herber R, Magdolou J, Haumont M, Bidault R, van Es H, Siest G. Glucuronidation of 3′-azido-3′-deoxythymidine in human liver microsomes: enzyme inhibition by drugs and steroid hormones. Biochim Biophys Acta 1992;1139:20-4.
24. Haumont M, Magdolou J, Lafaurie C, Ziegler JM, Siest G, Colin JN. Phenobarbital inducible UDP-glucuronosyltransferase is responsible for glucuronidation of 3′-azido-3′-deoxythymidine: characterization of the enzyme in human and rat liver microsomes. Arch Biochem Biophys 1990;281:264-70.
25. Macleod R, Eagling VA, Sim SM, Back DJ. In vitro inhibition studies of the glucuronidation of 3′-azido-3′-deoxythymidine catalyzed by human liver UDP-glucuronosyl transferase. Biochem Pharmacol 1992;43:382-6.
26. Cretton-Scott E, de Sousa G, Nicholas F, Rahmani R, Sommadossi JP. Methadone and its metabolite. N-demethyl methadone, inhibit ZDV glucuronidation in vitro [abstract]. Clin Pharmacol Ther 1996;59:168.
27. Griffin RJ, Burka LT, Cunningham ML. Activity of hepatic drug metabolizing enzymes following oxazepam-dosed feed treatment in B6c3F1 mice. Toxicol Lett 1995;76:251-6.
28. Reisine T, Pasternak G. Opioid analgesics and antagonists. In Hardman JG, Limbird LE, Molinoff PB, Ruddin RW, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996:521-6.
29. Peters WH, Kock L, Nagengast FM, Kremers PG. Biotransformation enzymes in human intestine: critical low levels in the colon? Gut 1991;4:408-12.
30. Peters WH, Nagengast FM, van Tongeren JH. Glutathione S-transferase, cytochrome p450, and uridine 5′-diphosphate-glucuronosyltransferase in human small intestine and liver. Gastroenterology 1989;96:783-9.
31. Selwyn PA, Feingold AR, Iezza A, et al. Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. Ann Intern Med 1989;111: 761-3.
32. Altice F, Motoshari F, Thompson AS, Friedland G. Perceptions, acceptance and adherence to antiretroviral therapy among prisoners [abstract]. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January, 1997.
33. Ling W, Rawson RA, Compton MA. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs 1994;26:119-28.
34. Kumar GN, Rodrigues AD, Buko AM, Denisson IF. Cytochrome P-450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharm Exp Ther 1996;277:423-31.